Biotechnology company developing genetically targeted small-molecule therapeutics for genetic cardiovascular diseases, initially hypertrophic and dilated cardiomyopathy
Biotechnology company developing genetically targeted small-molecule therapeutics for genetic cardiovascular diseases, initially hypertrophic and dilated cardiomyopathy. Its drug discovery platform combines cardiovascular genomics, heart muscle biology, and sarcomere biochemistry to identify mutation-specific treatments. MyoKardia combined with Bristol Myers Squibb.